-
WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany(1)
PharmaSources/Wuxi Biologics
January 16, 2020
WuXi Biologics will be the back-up manufacturer for Kovaltry™ of Bayer
-
A Review of the Policies/Events in 2019
PharmaSources/Suyi
January 15, 2020
5 policies in 2019 will affect China’s pharmaceutical market in 2020, which mainly involve China’s national medical insurance payment and pharmaceutical product cost control.
-
Speeding up review and guaranteeing payments: Blockbuster innovative drugs becoming truly accessible in China
En-CPhI.CN
January 14, 2020
The negotiated national reimbursement drug list (NRDL) of China in 2019 was issued on Nov. 28, 2019 as scheduled!
-
Discover the Latest Information and Seize Market Opportunities in the Annual Event of the CRO & CMO Industry at ICSE China 2020
PharmaSources/prnasia
January 13, 2020
The ICSE China 2020 will take place in Hall E2, E3/E7 of Shanghai New International Expo Centre from June 22-24, 2020.
-
Top 10 Pharmaceutical Products by Sales in the 2019H1
PharmaSources/Dopine
January 13, 2020
Humira Defending the Title, Ibrutinib Having Striking Performance, while Etanercept being Eye-popping.
-
The 2nd Chinese-Produced Adalimumab Biosimilar to be Approved for Marketing
PharmaSources/Xiaoyaowan
January 08, 2020
From the current pattern in China, rather than the price war, Chinese-produced adalimumab biosimilars shall work on at least the following aspects: to strive to enter the NRDL to solve patients’ worries about payment; to strive for more indications to exp
-
Important Progresses of New Drugs Marketed in China in 2019
En-CPhI.CN
January 07, 2020
Imported Drugs:1、Novartis CTL019 Applied for Clinical Trial in China to Officially Enter the Chinese Market Novartis f
-
Harvest in 2019 year-end with the Marketing of Multiple Generic Drugs
PharmaSources/Caicai
January 07, 2020
The NMPA is also “sprinting” as the year is coming to an end.
-
China’s First Innovative Drug for Alzheimer’s Disease: GV-971 Marketed at RMB895
PharmaSources/Dishui Sinan
January 06, 2020
The innovative drug for Alzheimer’s disease (AD)-GV-971 (sodium oligomannurarate) has been officially marketed in China, which is priced at RMB895/box and has attracted much attention of the pharmaceutical practitioners.
-
Chinese Autoimmune Disease Drug Market: Which of the Competing Global Blockbuster Drugs Will Win?
PharmaSources/1°C
December 05, 2019
Adalimumab has been “active” recently. Multiple adalimumab biosimilars are entering the harvest period in China following the arrival of China’s biosimilar era starting with ...